<p>在最新的季度中，16 位分析师对 Insmed（NASDAQ: INSM）提供了评级，展现出看涨和看跌的不同观点。</p>
<p>下表提供了他们最近评级的快速概览，突显出过去 30 天情绪的变化，并与前几个月进行比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师为 Insmed 设定了 12 个月的价格目标，显示出平均目标为 224.19 美元，最高预估为 269.00 美元，最低预估为 162.00 美元。当前的平均值反映出较之前的平均价格目标 222.00 美元增长了 0.99%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771610472_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771610472_0.png"/></p>
<h2>深入分析分析师评级：深入探索</h2>
<p>对金融专家如何看待 Insmed 的全面审查源于最近的分析师行动。以下是关键分析师、他们最近的评估以及评级和价格目标调整的详细总结。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>下调</td>
<td>超配</td>
<td>$208.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>上调</td>
<td>等权重</td>
<td>$162.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>宣布</td>
<td>超配</td>
<td>$231.00</td>
<td>-</td>
</tr>
<tr>
<td>Adam Walsh</td>
<td>Roth Capital</td>
<td>宣布</td>
<td>买入</td>
<td>$212.00</td>
<td>-</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超越大盘</td>
<td>$200.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>下调</td>
<td>买入</td>
<td>$215.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>下调</td>
<td>买入</td>
<td>$241.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>下调</td>
<td>买入</td>
<td>$225.00</td>
<td>$258.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>下调</td>
<td>买入</td>
<td>$230.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>下调</td>
<td>买入</td>
<td>$221.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>下调</td>
<td>超越大盘</td>
<td>$195.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>上调</td>
<td>超配</td>
<td>$234.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>上调</td>
<td>超配</td>
<td>$230.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>上调</td>
<td>买入</td>
<td>$258.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>上调</td>
<td>买入</td>
<td>$269.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>上调</td>
<td>超越大盘</td>
<td>$256.00</td>
<td>$196.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师根据不断变化的市场条件和公司表现频繁更新他们的建议。无论是'维持'、'上调'还是'下调'他们的立场，反映了他们对 Insmed 相关最新发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 揭示见解，分析师提供了对股票表现的定性见解，从'超越大盘'到'表现不佳'。这些评级传达了对 Insmed 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 通过获取见解，分析师提供了对 Insmed 股票未来价值的估计。这种比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
<p>为了获取有关 Insmed 市场表现的有价值见解，请考虑这些分析师评估以及关键财务指标。保持信息灵通，利用我们的评级表做出明智的决策。</p>
<p>随时了解 Insmed 分析师评级。</p>
<h2>关于 Insmed</h2>
<p>Insmed Inc 是一家生物制药公司，致力于改变患有严重和罕见疾病患者的生活。该公司的首个商业产品是 ARIKAYCE（阿米卡星脂质体吸入悬液），已在美国获得批准，用于治疗结核分枝杆菌复合体（MAC）肺病，作为成人患者有限或没有替代治疗选择的抗菌药物组合的一部分。它还在开发 Brensocatib，一种用于支气管扩张症和其他中性粒细胞介导疾病的口服可逆性二肽基肽酶 1 抑制剂，以及 Treprostinil Palmitil 吸入粉末，一种用于与间质性肺病和肺动脉高压相关的肺动脉高压的吸入型特雷普利酮前药。</p>
<h3>Insmed 的经济影响：分析</h3>
<p><strong>市值分析：</strong> 公司的市值低于行业基准，面临规模上的限制。这可能受到增长预期或运营能力等因素的影响。</p>
<p><strong>收入增长：</strong> Insmed 在过去 3 个月的收入增长显著。截至 2025 年 9 月 30 日，该公司的收入增长率约为 <strong>52.36%</strong>。这表明公司顶线收益的显著增加。与医疗保健行业的其他公司相比，该公司的增长率高于同行的平均水平。</p>
<p><strong>净利润率：</strong> Insmed 的净利润率超过行业标准，突显了公司的卓越财务表现。公司以 <strong>-259.95%</strong> 的净利润率有效管理成本，实现强劲盈利能力。</p>
<p><strong>股本回报率（ROE）：</strong> Insmed 的 ROE 落后于行业平均水平，表明在最大化股本回报方面面临挑战。ROE 为 <strong>-33.71%</strong>，公司可能在实现最佳财务表现方面面临困难。</p>
<p><strong>资产回报率（ROA）：</strong> Insmed 的 ROA 低于行业平均水平，表明在有效利用资产方面存在挑战。ROA 为 <strong>-15.29%</strong>，公司可能在从其资产中产生最佳回报方面面临困难。</p>
<p><strong>债务管理：</strong> Insmed 的债务与股本比率低于行业平均水平。该公司的比率为 <strong>0.61</strong>，这意味着它对债务融资的依赖较小，保持了债务与股本之间更健康的平衡，这对投资者来说是一个积极的信号。</p>
<h2>理解分析师评级的相关性</h2>
<p>在银行和金融系统领域，分析师专注于特定股票或定义的行业进行报告。他们的工作包括参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布股票的 &#34;分析师评级&#34;。分析师通常每季度评估和评级每只股票一次。</p>
<p>除了他们的评估外，一些分析师还通过提供关键指标的预测，如收益、收入和增长预期，来扩展他们的见解。这些补充信息为交易者提供了进一步的指导。重要的是要认识到，尽管他们是专业人士，分析师也是人，只能根据他们的信念提供预测。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

<p>在最新的季度中，16 位分析师对 Insmed（NASDAQ:INSM）给出了混合评级，平均 12 个月的目标价格为 224.19 美元，比之前的目标上涨了 0.99%。分析师们经常根据市场情况更新他们的建议，评级和目标价格也会发生显著变化。Insmed 的收入增长率约为 52.36%，但其净利润率和股本回报率低于行业平均水平。该公司的债务与股本比率保持在 0.61，表明对债务融资的依赖较小。分析师评级为股票表现和未来预期提供了洞察</p>

<p>In the latest quarter, 16 analysts provided ratings for Insmed (NASDAQ: INSM), showcasing a mix of bullish and bearish perspectives.</p>
<div class="lb-trans"><p>在最新的季度中，16 位分析师对 Insmed（NASDAQ: INSM）提供了评级，展现出看涨和看跌的不同观点。</p>
</div><p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他们最近评级的快速概览，突显出过去 30 天情绪的变化，并与前几个月进行比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts have set 12-month price targets for Insmed, revealing an average target of $224.19, a high estimate of $269.00, and a low estimate of $162.00. This current average reflects an increase of 0.99% from the previous average price target of $222.00.</p>
<div class="lb-trans"><p>分析师为 Insmed 设定了 12 个月的价格目标，显示出平均目标为 224.19 美元，最高预估为 269.00 美元，最低预估为 162.00 美元。当前的平均值反映出较之前的平均价格目标 222.00 美元增长了 0.99%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1771610472_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1771610472_0.png"/></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<div class="lb-trans"><h2>深入分析分析师评级：深入探索</h2>
</div><p>A comprehensive examination of how financial experts perceive Insmed is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>对金融专家如何看待 Insmed 的全面审查源于最近的分析师行动。以下是关键分析师、他们最近的评估以及评级和价格目标调整的详细总结。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$208.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$162.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$231.00</td>
<td>-</td>
</tr>
<tr>
<td>Adam Walsh</td>
<td>Roth Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$212.00</td>
<td>-</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$215.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$241.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$225.00</td>
<td>$258.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$230.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$221.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$234.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$258.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$269.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$256.00</td>
<td>$196.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>下调</td>
<td>超配</td>
<td>$208.00</td>
<td>$234.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>上调</td>
<td>等权重</td>
<td>$162.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Barclays</td>
<td>宣布</td>
<td>超配</td>
<td>$231.00</td>
<td>-</td>
</tr>
<tr>
<td>Adam Walsh</td>
<td>Roth Capital</td>
<td>宣布</td>
<td>买入</td>
<td>$212.00</td>
<td>-</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>上调</td>
<td>超越大盘</td>
<td>$200.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>下调</td>
<td>买入</td>
<td>$215.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>下调</td>
<td>买入</td>
<td>$241.00</td>
<td>$269.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>下调</td>
<td>买入</td>
<td>$225.00</td>
<td>$258.00</td>
</tr>
<tr>
<td>Andrew S. Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>下调</td>
<td>买入</td>
<td>$230.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>下调</td>
<td>买入</td>
<td>$221.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>下调</td>
<td>超越大盘</td>
<td>$195.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Benjamin Burnett</td>
<td>Wells Fargo</td>
<td>上调</td>
<td>超配</td>
<td>$234.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>上调</td>
<td>超配</td>
<td>$230.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>上调</td>
<td>买入</td>
<td>$258.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>上调</td>
<td>买入</td>
<td>$269.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>上调</td>
<td>超越大盘</td>
<td>$256.00</td>
<td>$196.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Insmed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insmed compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Insmed's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师根据不断变化的市场条件和公司表现频繁更新他们的建议。无论是'维持'、'上调'还是'下调'他们的立场，反映了他们对 Insmed 相关最新发展的反应。这些信息提供了分析师对公司当前状态的快照。</li>
<li><strong>评级：</strong> 揭示见解，分析师提供了对股票表现的定性见解，从'超越大盘'到'表现不佳'。这些评级传达了对 Insmed 相对于更广泛市场表现的预期。</li>
<li><strong>价格目标：</strong> 通过获取见解，分析师提供了对 Insmed 股票未来价值的估计。这种比较揭示了分析师预期随时间变化的趋势。</li>
</ul>
</div><p>For valuable insights into Insmed's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<div class="lb-trans"><p>为了获取有关 Insmed 市场表现的有价值见解，请考虑这些分析师评估以及关键财务指标。保持信息灵通，利用我们的评级表做出明智的决策。</p>
</div><p>Stay up to date on Insmed analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Insmed 分析师评级。</p>
</div><h2>About Insmed</h2>
<div class="lb-trans"><h2>关于 Insmed</h2>
</div><p>Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.</p>
<div class="lb-trans"><p>Insmed Inc 是一家生物制药公司，致力于改变患有严重和罕见疾病患者的生活。该公司的首个商业产品是 ARIKAYCE（阿米卡星脂质体吸入悬液），已在美国获得批准，用于治疗结核分枝杆菌复合体（MAC）肺病，作为成人患者有限或没有替代治疗选择的抗菌药物组合的一部分。它还在开发 Brensocatib，一种用于支气管扩张症和其他中性粒细胞介导疾病的口服可逆性二肽基肽酶 1 抑制剂，以及 Treprostinil Palmitil 吸入粉末，一种用于与间质性肺病和肺动脉高压相关的肺动脉高压的吸入型特雷普利酮前药。</p>
</div><h3>Insmed's Economic Impact: An Analysis</h3>
<div class="lb-trans"><h3>Insmed 的经济影响：分析</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值低于行业基准，面临规模上的限制。这可能受到增长预期或运营能力等因素的影响。</p>
</div><p><strong>Revenue Growth:</strong> Insmed's revenue growth over a period of 3M has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately <strong>52.36%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> Insmed 在过去 3 个月的收入增长显著。截至 2025 年 9 月 30 日，该公司的收入增长率约为 <strong>52.36%</strong>。这表明公司顶线收益的显著增加。与医疗保健行业的其他公司相比，该公司的增长率高于同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Insmed's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-259.95%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Insmed 的净利润率超过行业标准，突显了公司的卓越财务表现。公司以 <strong>-259.95%</strong> 的净利润率有效管理成本，实现强劲盈利能力。</p>
</div><p><strong>Return on Equity (ROE):</strong> Insmed's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-33.71%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> Insmed 的 ROE 落后于行业平均水平，表明在最大化股本回报方面面临挑战。ROE 为 <strong>-33.71%</strong>，公司可能在实现最佳财务表现方面面临困难。</p>
</div><p><strong>Return on Assets (ROA):</strong> Insmed's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-15.29%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> Insmed 的 ROA 低于行业平均水平，表明在有效利用资产方面存在挑战。ROA 为 <strong>-15.29%</strong>，公司可能在从其资产中产生最佳回报方面面临困难。</p>
</div><p><strong>Debt Management:</strong> Insmed's debt-to-equity ratio is below the industry average. With a ratio of <strong>0.61</strong>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> Insmed 的债务与股本比率低于行业平均水平。该公司的比率为 <strong>0.61</strong>，这意味着它对债务融资的依赖较小，保持了债务与股本之间更健康的平衡，这对投资者来说是一个积极的信号。</p>
</div><h2>Understanding the Relevance of Analyst Ratings</h2>
<div class="lb-trans"><h2>理解分析师评级的相关性</h2>
</div><p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish &#34;analyst ratings&#34; for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>在银行和金融系统领域，分析师专注于特定股票或定义的行业进行报告。他们的工作包括参加公司电话会议和会议，研究公司财务报表，并与内部人士沟通，以发布股票的 &#34;分析师评级&#34;。分析师通常每季度评估和评级每只股票一次。</p>
</div><p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<div class="lb-trans"><p>除了他们的评估外，一些分析师还通过提供关键指标的预测，如收益、收入和增长预期，来扩展他们的见解。这些补充信息为交易者提供了进一步的指导。重要的是要认识到，尽管他们是专业人士，分析师也是人，只能根据他们的信念提供预测。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</p>
</div>

深入解析 Insmed：16 位分析师分享他们的看法